SCHEMBL2603350

SCHEMBL2603350

CCCCCCCCCCc1ccc2c(=O)c(O)c(-c3ccc(O)c(O)c3)oc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 2/20 0.61
CDK5R1 Q15078 2/20 0.61
KDM4E B2RXH2 2/20 0.61
MEN1 O00255 2/20 0.61
TP53 P04637 2/20 0.61
CYP3A4 P08684 2/20 0.61
MAPT P10636 2/20 0.61
CYP2C9 P11712 2/20 0.61
ALOX15 P16050 2/20 0.61
ALOX12 P18054 2/20 0.61
CDK2 P24941 2/20 0.61
MAPK1 P28482 2/20 0.61
RECQL P46063 2/20 0.61
KMT2A Q03164 2/20 0.61
HSD17B10 Q99714 2/20 0.61
AMY1A P0DUB6 2/20 0.61
SLCO2B1 O94956 1/20 0.61
CCNB2 O95067 1/20 0.61
ALDH1A1 P00352 1/20 0.61
LMNA P02545 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13648970 0.91 MEN1 (0.60) CDK5CDK5R1KDM4EMEN1TP53
SCHEMBL4043863 0.91 MEN1 (0.60) CDK5CDK5R1KDM4EMEN1TP53
SCHEMBL582170 0.91 MEN1 (0.60) CDK5CDK5R1KDM4EMEN1TP53
SCHEMBL12639915 0.91 MEN1 (0.60) CDK5CDK5R1KDM4EMEN1TP53
SCHEMBL4034075 0.91 MEN1 (0.60) CDK5CDK5R1KDM4EMEN1TP53
SCHEMBL4043879 0.91 MEN1 (0.60) CDK5CDK5R1KDM4EMEN1TP53
SCHEMBL4044129 0.91 MEN1 (0.60) CDK5CDK5R1KDM4EMEN1TP53
SCHEMBL4038490 0.89 ABCB1 (0.55) CDK5CDK5R1KDM4EMEN1TP53
SCHEMBL29633051 0.86 CYP3A4 (0.60) KDM4EMEN1TP53CYP3A4MAPT
SCHEMBL4034126 0.86 MEN1 (0.62) CDK5CDK5R1KDM4EMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188144-B2 In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells ANTOXIS LIMITED (GB) 2012-05-29 US disclosed
US-8188144-B2 In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells ANTOXIS LIMITED (GB) 2012-05-29 US disclosed
US-20120094384-A1 USE OF COMPOUNDS FOR DIFFERENTIATION OF CELLS ANTOXIS LIMITED (GB) 2012-04-19 US disclosed
US-20120094384-A1 USE OF COMPOUNDS FOR DIFFERENTIATION OF CELLS ANTOXIS LIMITED (GB) 2012-04-19 US disclosed
US-20100267132-A1 IN VITRO PRESERVATION OF LIVING ANIMAL CELLS AND COMPOUNDS SUITABLE FOR USE IN THE PRESERVATION OF LIVING ANIMAL CELLS ANTOXIS LIMITED (GB) 2010-10-21 US disclosed
US-20100267132-A1 IN VITRO PRESERVATION OF LIVING ANIMAL CELLS AND COMPOUNDS SUITABLE FOR USE IN THE PRESERVATION OF LIVING ANIMAL CELLS ANTOXIS LIMITED (GB) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267132-A1 IN VITRO PRESERVATION OF LIVING ANIMAL CELLS AND COMPOUNDS SUITABLE FOR USE IN THE PRESERVATION OF LIVING ANIMAL CELLS PIGS, AQP1, F12 CDK5 3928/4885CDK5R1 4254/4885KDM4E 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.